Compass Therapeutics‘ CTX-2026, an antibody targeting the protein BTN3A1, could be therapeutic in ovarian cancer by helping the immune system destroy cancer cells, preclinical data show. The study, “BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells,” was published in the journal Science. The body’s immune system is responsible for fighting off infections and killing unhealthy cells, including cancer cells. Fundamentally, the immune system must be able to recognize and attack infected or…
You must be logged in to read/download the full post.
The post Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study appeared first on BioNewsFeeds.